Who are Methotrexate 1% Topical Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate, Cellcept, Leustatin, Fudr, Cytarabine, Imuran.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-1-topical-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Methotrexate 1% Topical Gel — Competitive Intelligence Brief

Methotrexate 1% Topical Gel (Methotrexate 1% Topical Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; Immunosuppressant. Area: Dermatology.

marketed Antimetabolite; Immunosuppressant Dihydrofolate reductase (DHFR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate 1% Topical Gel (Methotrexate 1% Topical Gel) — Jinnah Postgraduate Medical Centre. Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis in rapidly dividing cells, with immunosuppressive and anti-inflammatory effects when applied topically.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methotrexate 1% Topical Gel TARGET	Methotrexate 1% Topical Gel	Jinnah Postgraduate Medical Centre	marketed	Antimetabolite; Immunosuppressant	Dihydrofolate reductase (DHFR)
Mycophenolate	MYCOPHENOLIC ACID	Novartis	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	2004-01-01
Cellcept	MYCOPHENOLATE MOFETIL	Roche Palo	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	1995-01-01
Leustatin	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	marketed	Antimetabolite	DNA polymerase	1969-01-01
Imuran	AZATHIOPRINE	Legacy Pharma	marketed	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-11-23 — Leustatin · 10849919 · Method of Use · US
2039-08-16 — Cellcept · 12097284 · Formulation · US
2039-08-16 — Cellcept · 12226526 · Formulation · US
2039-08-16 — Cellcept · 11931455 · Formulation · US
2039-08-16 — Cellcept · 12194143 · Formulation · US
2039-08-16 — Cellcept · 12097285 · Formulation · US
2041-09-10 — Leustatin · 12539329 · Method of Use · US
2041-09-10 — Leustatin · 12533408 · Method of Use · US

Sponsor landscape (Antimetabolite; Immunosuppressant class)

Jinnah Postgraduate Medical Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate 1% Topical Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-1-topical-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab